Pfizer is partnering with a firm in China to make its COVID-19 drug Paxlovid available in the country in the first half of 2023, Bloomberg’s Nacha Cattan and Immanual Milton report, citing a presentation by its CEO Albert Bourla. The report indicates that production has not started yet but will soon.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Pfizer sees 2025 potential non-COVID revenues excluding BD of about $52B
- Moderna considering $110-$130 for COVID shot, similar to Pfizer’s, WSJ says
- Pfizer in talks to license Chinese drugmakers for generic Paxlovid, Reuters says
- Pfizer: FDA accepts for priority review sBLA for 20vPnC
- Morgan Stanley sees Moderna’s phase 3 RSV vaccine data as catalyst-driven idea